Association between the use of anticholinergic antiparkinson drugs and safety and receptor drug-binding profiles of antipsychotic agents

European Journal of Clinical Pharmacology
Pål GjerdenJørgen G Bramness


The use of anticholinergic antiparkinson drugs is almost exclusively confined to treating antipsychotic-induced extrapyramidal side effects (EPS). We investigated the prevalence of concomitant prescription of anticholinergics as a proxy for antipsychotic-induced EPS and compared variance in prevalence with differences in the assumed mechanisms of action of antipsychotics on central nervous system (CNS) transmitter systems (i.e., receptor drug-binding profiles). We paid special attention to potential differences between typical and atypical antipsychotics. Data were drawn from the Norwegian Prescription Database on sales of antipsychotic and anticholinergic antiparkinson drugs to a total of 57,130 outpatients in 2004. We assessed concomitant dispensations of antipsychotic and anticholinergic drugs and correlated the prevalence of concomitantly prescribed anticholinergics to previously assessed receptor-binding profiles of antipsychotics. The concurrent use of anticholinergics varied between 0.4% and 26.0% for patients using a single antipsychotic agent. The prevalence of anticholinergic comedication was more than twice as high in patients using two or more antipsychotic drugs. Four typical antipsychotics (fluphenazine, zuclopent...Continue Reading


Mar 12, 2003·Neuropsychopharmacology : Official Publication of the American College of Neuropsychopharmacology·Wesley K KroezeBryan L Roth
Jun 11, 2003·Archives of General Psychiatry·John M DavisIra D Glick
Dec 4, 2003·JAMA : the Journal of the American Medical Association·Robert RosenheckUNKNOWN Department of Veterans Affairs Cooperative Study Group on the Cost-Effectiveness of Olanzapine
Aug 2, 2005·The British Journal of Psychiatry : the Journal of Mental Science·Sylvia ParkStephen B Soumerai
Sep 21, 2005·The New England Journal of Medicine·Jeffrey A LiebermanUNKNOWN Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) Investigators
Jan 18, 2006·Progress in Neuro-psychopharmacology & Biological Psychiatry·S Nassir GhaemiFrederick K Goodwin
Aug 22, 2006·CNS & Neurological Disorders Drug Targets·Martyn D WoodDeclan N C Jones
Feb 5, 2008·Schizophrenia Research·Rajiv TandonUNKNOWN Section of Pharmacopsychiatry, World Psychiatric Association
Mar 18, 2008·Journal of Clinical Psychopharmacology·Keming GaoJoseph R Calabrese
May 9, 2008·Journal of Evaluation in Clinical Practice·Pål GjerdenLars Slørdal
Dec 20, 2008·British Journal of Clinical Pharmacology·Pål GjerdenLars Slørdal

❮ Previous
Next ❯


Jun 4, 2010·European Journal of Clinical Pharmacology·Pål GjerdenJørgen G Bramness
May 21, 2011·General Hospital Psychiatry·Mercedes KwiatkowskiChristopher C White
Aug 13, 2015·SpringerPlus·Tiago Sousa Veloso, Mariana Seixas Cambão
Dec 9, 2014·Forensic Science International : Synergy·Jørgen G BramnessVigdis Vindenes
Nov 9, 2015·European Archives of Psychiatry and Clinical Neuroscience·Kjetil N JørgensenIngrid Agartz

❮ Previous
Next ❯

Related Concepts

Related Feeds

Antipsychotic Drugs

Antipsychotic drugs are a class of medication primarily used to manage psychosis (including delusions, hallucinations, paranoia or disordered thought), principally in schizophrenia and bipolar disorder. Discover the latest research on antipsychotic drugs here

Basal Ganglia

Basal Ganglia are a group of subcortical nuclei in the brain associated with control of voluntary motor movements, procedural and habit learning, emotion, and cognition. Here is the latest research.